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COMPARISON BETWEEN E-TEST AND CLSI BROTH MICRODILUTION METHOD FOR ANTIFUNGAL
SUSCEPTIBILITY TESTING OF Candida albicans ORAL ISOLATES
Cristiane Yumi KOGA-ITO(1), Juliana Pereira LYON(2) & Maria Aparecida de RESENDE(3)
SUMMARY
Thirty Candida albicans isolated from oral candidosis patients and 30 C. albicans isolated from control individuals were
studied. In vitro susceptibility tests were performed for amphotericin B, fluconazole, 5-flucytosine and itraconazole through the
Clinical and Laboratorial Standards Institute (CLSI) reference method and E test system. The results obtained were analyzed and
compared. MIC values were similar for the strains isolated from oral candidosis patients and control individuals. The agreement
rate for the two methods was 66.67% for amphotericin B, 53.33% for fluconazole, 65% for flucytosine and 45% for itraconazole.
According to our data, E test method could be an alternative to trial routine susceptibility testing due to its simplicity. However, it
can not be considered a substitute for the CLSI reference method.
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INTRODUCTION
Candida albicans is a commensal yeast of the normal oral microbiota.
However, several local and systemic factors can predispose to the
development of oral candidosis. Thus, conditions such as age extremes,
immunodeficiency, endocrine disorders, radiotherapy, malignant diseases,
xerostomia, denture wearing, poor oral hygiene and orthodontic treatment
can be cited as predisposing factors4,12,19,22. Nystatin and amphotericin B
are common therapeutic agents for oropharyngeal candidosis21. The
increasing number of clinical isolates resistant to antifungal therapy, as
well as the necessity of a guide to the selection and follow-up of the
treatment led to a demand for susceptibility testing of fungi13. For this
purpose, the Clinical and Laboratorial Standards Institute (CLSI)
approved a reference method for antifungal susceptibility testing of
yeasts, the National Committee for Clinical and Laboratorial Standards
(NCCLS) M-27 A2 document14. The E test1 has been introduced as an
easier testing procedure and an alternative for the NCCLS
method2,6,15,17,20,23. The great advantage of E test is the simplicity of the
methodology. However, not all antifungal agents are available in E test
and there is a difficulty associated with endpoint interpretation, due to
the growth of micro-colonies in the inhibition zone, leading to lower
reproducibility when the test is performed by several technicians. The
aim of this study was to compare the results of fluconazole, itraconazole,
flucytosine and amphotericin B susceptibility testing of C. albicans oral
strains obtained by the CLSI reference method and the E test.
MATERIALS AND METHODS
Isolates: Thirty Candida albicans isolated from denture-associated
oral candidosis patients and 30 from control individuals were studied.
The patients with candidosis were randomly selected among the patients
of the Prosthetics Department of São José dos Campos Faculty of
Dentistry (University of the State of São Paulo-UNESP, São Paulo,
Brazil). No patient was under treatment with antifungal drugs. The
individuals from the control group were randomly selected among
students from this University. Patients with basis diseases or smokers
or under medication were excluded. The strains were isolated from
saliva and identified by biochemical, physiological and morphological
tests. Candida spp. strains were transferred onto Sabouraud dextrose
agar (Difco Laboratories, Detroit, USA) and stored at 4 °C. C. albicans
strains were transferred onto fresh Sabouraud dextrose agar (Difco
Laboratories, Detroit, USA) slants 24 hours prior the realization of
antifungal susceptibility testing.
Susceptibility testing:
1. NCCLS reference method: The susceptibility assays were
determined by the microbroth dilution method performed in sterile flat-
bottom 96-well microplates (Difco Laboratories, Detroit, USA) as
described previously in NCCLS guidelines, M-27 A document (NCCLS,
2002). Briefly, isolates were inoculated at 35 °C and observed at 24 and
48 hours. Five colonies greater than 1 mm in diameter were selected,
suspended in saline solution and adjusted to a final concentration of 0.5
x 103 to 2.5 x 103 in RPMI 1640 medium (Sigma, St. Louis, USA) buffered
to pH 7.0 with 0.165M morpholinepropanesulfonic acid (MOPS; Sigma).
The antifungal agents fluconazole (Pfizer, São Paulo, Brazil), itraconazole
(Janssen Pharmaceutica, São Paulo, Brazil), amphotericin B (Sigma)
and flucytosine (5-fluorocytosine; Hoffman La Roche, Basel,
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Switzerland) were used in the susceptibility tests. Amphotericin B and
itraconazole were dissolved in dimethylsulfoxide. Fluconazole and
flucytosine were dissolved in sterile distilled water. The drugs were
prepared at the following concentrations: 320 µg/mL for amphotericin
B, 1000 µg/mL for flucytosine, 1250 µg/mL for fluconazole and 640 µg/
mL for itraconazole. The solutions were diluted in RPMI medium and
final drugs concentrations ranged from 32 to 0.04 µg/mL for amphotericin
B, 64 to 0.04 µg/mL for itraconazole, 25 to 0.02 µg/mL for flucytosine
and 128 to 0.06 µg/mL for fluconazole. After 48 hours of incubation at
35 °C, MIC (minimum inhibitory concentration) was determined visually
by comparing its turbidity with the drug-free growth control well. For
the azoles and flucytosine the MIC values were defined as the lower
drug concentration which resulted in reduction of 80% in the turbidity
in comparison with the drug-free growth control well and for amphotericin
B the MIC value was defined as the lowest drug concentration for which
the well was optically clear.
2. E test (AB Biodisk, Solna, Sweden): The E test was performed
according to the manufacturer’s instructions (AB Biodisk, 1993). In
brief, the inoculum concentration was adjusted to 0.5 in McFarland
standard for Candida species. Then, 0.5 mL of this suspension was
inoculated onto plates containing RPMI 1640 agar (1.5%) with 2%
glucose using a cotton swab. After a period of 15 minutes, the E test
strips were applied. The antifungal drugs amphotericin B, itraconazole,
fluconazole, and flucytosine were tested. The plates were incubated at
35 °C and read after 24 and 48 hours.
Analysis of the results: The MICs (minimum inhibitory
concentration) at which 50% (MIC50) and 90% (MIC90) of the isolates
were inhibited were determined for each drug. A comparison between
the results obtained by the NCCLS reference method and E test was
performed. The rate of agreement was represented as proposed by
SEWELL et al. (1994) in terms of percentage of agreement. It was
considered agreement when MIC results of E test and NCCLS method
were in exact agreement or were within ± 2 two-fold dilutions. The
results were descriptively analyzed.
RESULTS
The MIC ranges and values of MIC50 and MIC90 obtained for
amphotericin B, fluconazole, itraconazole and flucytosine susceptibility
testings determined by NCCLS method and E test are summarized in
Table 1 and 2, respectively. MIC values were similar for the strains
isolated from oral candidosis patients and control individuals.
Table 1
In vitro susceptibility testing of amphotericin B, fluconazole, itraconazole and flucytosine determined by NCCLS reference method
Groups MIC ranges (µg/mL) MIC50 MIC90
24 h 48 h 24 h 48 h 24 h 48 h
Control group
Amphotericin B 0.04 - 1 0.08 - 2 0.125 0.25 1 2
Fluconazole ´1 - 16 ´1 - 16 2 4 8 16
Flucytosine 0.012 - 0.19 0.012 - 0.78 0.049 0.09 0.19 0.78
Itraconazole 0.04 - 2 0.04 - 2 0.25 0.5 1 4
Candidosis group
Amphotericin B 0.08 - 2 0.08 - 2 0.5 1 4 8
Fluconazole 0.5 - 16 0.5 - 16 2 8 32 64
Flucytosine 0.012 - 0.39 0.012 - 0.39 0.049 0.19 0.19 0.78
Itraconazole 0.125 - 4 0.125 - 4 0.5 2 4 16
MIC - minimum inhibitory concentration
Table 2
In vitro susceptibility testing of amphotericin B, fluconazole, itraconazole and flucytosine determined by E test.
Groups MIC ranges (µg/mL) MIC50 MIC90
24 h 48 h 24 h 48 h 24 h 48 h
Control group
Amphotericin B <0.03 - 0.75 <0.03 - 0.75 0.125 0.5 1 2
Fluconazole 0.125 - >256 0.023 - >256 0.5 0.5 1 1
Flucytosine 0.003 - >32 0.006 - >32 0.023 0.032 0.125 0.125
Itraconazole 0.006 - 24 0.006 - >32 0.047 0.064 0.5 0.5
Candidosis group
Amphotericin B 0.094 - 0.5 0.094 - 0.5 0.25 0.5 0.5 0.5
Fluconazole 0.064 - 16 0.064 - 16 0.25 0.25 0.75 0.75
Flucytosine 0.003 - 32 0.003 - >32 0.023 0.023 0.032 0.047
Itraconazole 0.016 - >32 0.016 - >32 0.064 0.064 0.25 0.75
MIC - minimum inhibitory concentration
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The comparison of the MICs values obtained by NCCLS reference
method and E test at 24 h and 48 h were compared and the percentages
of agreement are presented in Table 3.
DISCUSSION
The comparison between E test and CLSI methodology has been
studied by several authors. Earlier studies related a good agreement
between the NCCLS reference microdilution method and the E test for
the azoles susceptibility testing. In these researches, the agreement
percentages varied from 71 to 85.2% for ketoconazole6,9, from 80 to
96% to fluconazole7,20,23 and from 80 to 84% for itraconazole. However,
in more recent publications, authors related poorer agreement
percentages between these two susceptibility testing methods. KOC et
al.9 and MARTIN-MAZUELOS11 related percentages of 74-79% for
fluconazole. For itraconazole, MARTIN-MAZUELOS11 obtained
61.4% of agreement.
In the present study, poor agreement was observed for fluconazole
(53.33%) and itraconazole (45%) at 24 hours. Additionally, agreement
observed at 48 hours was even worst. ESPINEL-INGROFF7 also related
a poorer agreement after 48 hours of incubation in comparison with
results observed in 24 hours.
The determination of the endpoints for the azoles is a significant
factor in the variability of MIC results. The partial growth inhibition
makes it difficult to determine MIC values accurately3,18. The same
person always performed the interpretation of MIC results in the CLSI
method. Similarly, to avoid variability in endpoint readings due to the
difficulty in define the borders of inhibition zone in the E test method,
the same person scored all the plates.
PFALLER et al.16 obtained the best agreement between the NCCLS
reference method and the E test using the RPMI agar with 2% glucose.
For this reason, all E test experiments were performed with this type
of medium.
For amphotericin B susceptibility testing, good correlation was
observed between the tested methods at 24h (66.67%) and 48 hours.
Interestingly, best agreement percentage was observed after 48 hours
(71.67%). VAN ELDERE et al.23 and KOC et al. 9 also related good
agreement rates that varied from 90 to 96%.
For flucytosine, a good agreement between the NCCLS method
and E test was observed at 24 hours (65%). These results are in
accordance to those obtained by CHANG et al.5 and ISHIGAKI et al.8.
At 48 hours, a moderated correlation could be observed (43.33%).
The present study demonstrated a lower percentage of agreement
between the methodologies tested than other studies found in literature.
The discrepancy might be due to interlaboratory differences or to the
use of different media for E test methodology. This fact reinforces the
importance of tests standardization. On the other hand, it is relevant to
notice that the evaluator was not blind regarding the test or for the
antifungal agent evaluated, which might be considered a limitation of
the present work.
Minimmum inhibitory concentrations obtained in the present study
were similar for control samples and samples obtained from candidosis
patients. A higher MIC could possibly be expected for candidosis
patients, since virulence factors such as exoenzyme production have
been correlated with antifungal resistance10.
In conclusion, E test method could be considered an alternative to
trial routine susceptibility testing due to its simplicity. However, it can
not be considered, at this moment, a substitute for NCCLS reference
method, since a complete agreement between both methodologies has
not been reached, as demonstrated by the present study and corroborated
by others presented in literature. Due to the numerous variables
associated to the E test method, further studies must be performed to
standardize the medium and incubation conditions. Moreover, studies
on the correlation of in vitro antifungal susceptibility testing and clinical
response to these drugs are essentially important.
RESUMO
Comparação entre E-test e o método da microdiluição do CLSI
para teste de susceptibilidade a antifúngicos de isolados orais de
Candida albicans
Trinta Candida albicans isoladas de pacientes portadores de
candidose oral e 30 Candida albicans isoladas de indivíduos controle
foram estudadas. Testes de susceptibilidade in vitro foram realizados
com anfotericina B, fluconazol, 5-flucitosina e itraconazol pelo método
do Clinical and Laboratorial Standars Institute (CLSI) e por E-test. Os
resultados obtidos foram analisados e comparados. Os valores de CIM
foram semelhantes para amostras isoladas de pacientes portadores de
candidose oral e indivíduos controle. A concordância entre os dois
métodos foi de 66,7% para a anfotericina B, 53,33% para o fluconazol,
65% para a flucitosina e 45% para o itraconazol. De acordo com estes
Table 3
Percentage of agreement (exact agreement or within + 2 two-fold dilutions)
between the MIC (minimum inhibitory concentration) values obtained by
NCCLS method and E test
Antifungal drug Percentage of agreement
24 h 48 h
Amphotericin B
 - control group 50% 73.33%
 - candidosis group 83.33% 70%
Average 66.67% 71.67%
Fluconazole
 - control group 53.33% 1.67%
 - candidosis group 53.33% 1%
Average 53.33% 1.34%
Flucytosine
 - control group 83.33% 50%
 - candidosis group 46.67% 36.66%
Average 65% 43.33%
Itraconazole
 - control group 40% 33%
 - candidosis group 50% 36.66%
Average 45% 34.83%
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resultados, o método do E-test poderia ser uma alternativa para a
triagem de casos de rotina pela sua simplicidade. Entretanto, este
método não pode ser considerado como um substituto para o método
de referência do CLSI.
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